ClinicalTrials.gg
Active, not recruitingNCT03451851PROTOSTARUpdated Nov 3, 2026Results posted

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

A Phase 3 interventional study of Guselkumab and Placebo for guselkumab in Psoriasis, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 39 sites in 9 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Enrollment
15th of 29
120 · median 120
Started
2018
with 1 other
Phase 3
12 of 29
none open now
Registered
12th of 29
by date
Lead sponsor
9 of 29
Janssen Research & Development, LLC

Among the 29 studies testing guselkumab in Psoriasis, this one is the 15th largest by enrollment, is one of 2 that started in 2018, is one of 12 in phase 3, and was the 12th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of chronic plaque-type psoriasis for at least 6 months (with or without psoriatic arthritis [PsA]), prior to first administration of study intervention, defined as having at screening and baseline, Investigator Global Assessment (IGA) greater than or equal to (>=) 3, Psoriasis Area and Severity Index (PASI) >=12, >=10% body surface area (BSA) involvement and at least one of the following: very thick lesions, facial, genital, or hand/ foot involvement, PASI>=20, >20% BSA involvement, or IGA=4
  • Be a candidate for phototherapy or systemic treatment of plaque psoriasis (either naive or history of previous treatment)
  • Have plaque psoriasis considered by the investigator as inadequately controlled with phototherapy and/or topical therapy after an adequate dose and duration of therapy
  • Be considered, in the opinion of the investigator, a suitable candidate for etanercept therapy, according to their country's approved Enbrel product labeling
  • Be otherwise healthy on the basis of physical examination, medical history, and vital signs performed at screening. Any abnormalities, must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and initialed by the investigator
  • Must have acceptable evidence of immunity to varicella and measles, mumps, and rubella (MMR), which includes any one of the following: documentation of age-appropriate vaccination that includes both doses of each vaccine (unless local guidelines specify otherwise) or documentation of past infection by a healthcare provider or in the absence of previous 2 criteria, participants must have positive protective antibody titers to these infection prior to the first administration of study intervention. For participants who have not completed the recommended vaccination schedule for varicella and MMR, and the subsequent vaccination falls within the next 4 years, an accelerated vaccination schedule must be completed prior to study enrollment if available and required or strongly recommended for the location. If varicella or MMR vaccines are utilized, it is necessary for 2 weeks to elapse between the vaccination and receipt of study intervention

Exclusion criteria

Exclusion Criteria:

  • Currently has nonplaque forms of psoriasis (example, erythrodermic, guttate, or pustular)
  • Has current drug-induced psoriasis (example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Has previously received guselkumab or etanercept
  • Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic non-remitting cystitis), fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers
  • Has a known history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Part 1 Group 1: Guselkumab

    Participants in Part 1a (age greater than or equal to (\>=) 12 - less than (\<) 18 years) will receive a weight-based dose of guselkumab subcutaneously (SC) at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of guselkumab until they lose \>=50% of their Week 16 PASI response, then they receive 1 dose guselkumab, followed by a dose 4 weeks later, and every 8 weeks (q8w) thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a placebo injection at Week 16 and continue to receive guselkumab q8w from Week 20 through Week 52. Participants who are eligible and willing to continue guselkumab may enter the Long Term Extension (LTE) Phase of the study. Part 1b (age \>= 6 - \<12 years) will follow the same dosing and commence after Part 1a data review.

    Drug: Guselkumab · Drug: Placebo for guselkumab

  • Placebo comparator
    Part 1 Group 2: Placebo for Guselkumab

    Participants in Part 1a (age \>= 12 - \<18 years) will receive placebo for guselkumab administered SC at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of study intervention until they lose \>=50% of their Week 16 PASI response, at which time they will receive a weight-based guselkumab SC dose, followed by a dose 4 weeks later, and q8w thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a weight-based guselkumab dose at Weeks 16 and 20, followed by q8w dosing thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age \>= 6 - \<12 years) will follow the same dosing and commence after Part 1a data review.

    Drug: Guselkumab · Drug: Placebo for guselkumab

  • Active comparator
    Part 1 Group 3: Etanercept

    Participants in Part 1a (age \>= 12 - \<18 years) will receive weight-based etanercept dose up to 50 milligram SC weekly through Week 15. Participants who elect to continue in the study will receive a weight-based guselkumab dose at Weeks 20 and 24, followed by q8w dosing thereafter through Week 48. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age \>= 6 - \<12 years) will follow the same dosing and commence after Part 1a data review.

    Drug: Guselkumab · Drug: Etanercept

  • Experimental
    Part 2: Guselkumab

    Participants will receive a weight-based dose of open-label guselkumab SC at Weeks 0, 4 and q8w thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab at Week 52 and q8w thereafter.

    Drug: Guselkumab

Interventions

  • Participants will receive a weight-based dose of guselkumab subcutaneously.

    Also known as: CNTO1959

  • DrugPlacebo for guselkumab

    Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.

  • Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.

    Also known as: Enbrel

06

What researchers measure

Primary outcomes

  1. Part 1: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: At Week 16

  2. Part 1: Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16

    The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 75 response represented participants who achieved at least a 75 % improvement from baseline in the PASI score.

    Time frame: At Week 16

Secondary outcomes

  1. Part 1: Percentage of Participants Who Achieve PASI 90 Response at Week 16

    The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90 % improvement from baseline in the PASI score.

    Time frame: At Week 16

  2. Part 1: Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: At Week 16

  3. Part 1: Percentage of Participants Who Achieved PASI 100 Response at Week 16

    The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 100 response represented participants who achieved a 100 % improvement from baseline in the PASI score.

    Time frame: At Week 16

  4. Part 1: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Score at Week 16

    CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. Change from baseline is defined as post baseline score minus baseline score.

    Time frame: Baseline and Week 16

  5. Part 1: Percentage of Retreated Participants Who Achieved a PASI 90 Response Over Time After Retreatment

    PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90 % improvement from baseline in PASI score.

    Time frame: At 4 and 8 weeks post retreatment (retreatment period ranged from Week 16 to Week 52)

  6. Part 1: Percentage of Retreated Participants Who Achieved PASI Responses (PASI 50, 75, 90, and 100) Over Time After Retreatment

    The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90 and 100 response represented at least 50, 75, 90 and 100% improvement from baseline respectively, in the PASI score.

    Time frame: At 4 and 8 weeks post retreatment (retreatment period ranged from Week 16 to Week 52)

  7. Part 1: Percentage of Retreated Participants Who Achieved IGA Responses (IGA of Cleared [0], Minimal [1], or Mild [2], IGA of Cleared [0] or Minimal [1], and IGA of Cleared [0]) Over Time After Retreatment

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: At 4 and 8 weeks post retreatment (retreatment period ranged from Week 16 to Week 52)

  8. Part 1: Cumulative Rate of Loss of at Least 50% of Week 16 PASI Improvement Through Week 52 Among Guselkumab PASI 90 Responders at Week 16

    Cumulative rate of loss of at least 50% of PASI improvement was defined as percentage of participants with a loss of \>=50% of Week 16 PASI improvement after treatment is withdrawn. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease.

    Time frame: Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52

  9. Part 1: Cumulative Maintenance Rate of PASI 90 Response Through Week 52 Among Guselkumab PASI 90 Responders at Week 16

    Cumulative maintenance rate was defined as percentage of participants who maintained their PASI 90 response through Week 52 among guselkumab PASI 90 responders at Week 16. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90% improvement from baseline in PASI score.

    Time frame: Week 20, 24, 28, 32, 36, 40, 44, 48, and 52

  10. Part 1: Percentage of Participants Who Achieved a PASI 50 Response at Week 16

    The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 50 response represented at least a 50% improvement from baseline in the PASI score.

    Time frame: At Week 16

  11. Part 1: Percent Improvement From Baseline in PASI Through Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease.

    Time frame: Weeks 4, 8, 12, and 16

  12. Part 2: Percent Improvement From Baseline in PASI Through Week 52

    The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease.

    Time frame: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

  13. Part 1: Percentage of Participants With PASI Responses (PASI 50, 75, 90, and 100) Through Week 16

    The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90, and 100 responses represented at least 50%, 75%, 90%, and 100% improvement from baseline respectively, in the PASI score.

    Time frame: Weeks 4, 8, 12, and 16

  14. Part 2: Percentage of Participants With PASI Responses (PASI 50, 75, 90, and 100) Through Week 52

    The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90, and 100 responses represented at least 50%, 75%, 90%, and 100% improvement from baseline respectively, in the PASI score.

    Time frame: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

  15. Part 1: Percentage of Participants With IGA of Cleared (0), Cleared (0) or Minimal (1), Mild or Better (<=2) Through Week 16

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: Weeks 4, 8, 12, and 16

  16. Part 2: Percentage of Participants With IGA of Cleared (0), Cleared (0) or Minimal (1), Mild or Better (<=2) Through Week 52

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

  17. Part 2: Change From Baseline in CDLQI Score Through Week 52

    Change from baseline in CDLQI score through Week 52 were reported. CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.

    Time frame: Baseline, Weeks 8, 16, 28, 36, and 52

  18. Part 1: Percentage of Participants With CDLQI Score Equal to 0 or 1 at Week 16 Among Participants With a Baseline CDLQI Score Greater Than (>) 1

    CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.

    Time frame: At Week 16

  19. Part 2: Percentage of Participants With CDLQI Score Equal to of 0 or 1 Through Week 52 Among Participants With a Baseline CDLQI Score > 1

    CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.

    Time frame: Weeks 8, 16, 28, 36, and 52

  20. Part 1: Percentage of Participants With Family Dermatology Life Quality Index (FDLQI) of 0 or 1 at Week 16 Among Participants With a Baseline FDLQI >1

    The FDLQI was a 10-item questionnaire that examined the impact of participant's skin disease on different aspects of their QoL (example: emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) were added to give a total scale score that ranged from 0 to 30; a higher score indicated greater impairment of QoL.

    Time frame: At Week 16

  21. Part 2: Percentage of Participants With Family Dermatology Life Quality Index (FDLQI) of 0 or 1 Through Week 52 Among Participants With a Baseline FDLQI >1

    The FDLQI was a 10-item questionnaire that examine the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) were added to give a total scale score that ranged from 0 to 30; a higher score indicates greater impairment of QoL.

    Time frame: Weeks 8, 16, 28, 36, and 52

  22. Part 1: Change From Baseline in FDLQI Score at Week 16

    The FDLQI was a 10-item questionnaire that examined the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) are added to give a total scale score that ranged from 0 to 30; a higher score indicates greater impairment of QoL.

    Time frame: Baseline and Week 16

  23. Part 2: Change From Baseline in FDLQI Score Through Week 52

    The FDLQI was a 10-item questionnaire that examine the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) are added to give a total scale score that ranged from 0 to 30; a higher score indicated greater impairment of QoL.

    Time frame: Baseline, Weeks 8, 16, 28, 36, and 52

  24. Part 1: Change From Baseline in Body Surface Area (BSA) With Psoriasis Skin Involvement at Week 16

    Change from baseline in percent body surface area with psoriasis skin involvement was reported. BSA as physical measure to define disease severity is to determine how much of the BSA is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.

    Time frame: Baseline and Week 16

  25. Parts 2: Change From Baseline in BSA With Psoriasis Skin Involvement Over Time Through Week 52

    Change from baseline in percent body surface area with psoriasis skin involvement was reported. BSA as physical measure to define disease severity is to determine how much of the BSA is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

  26. LTE Phase: Percentage of Participants Who Achieved PASI Responses (PASI 50, 75, 90, and 100) Over Time

    Time frame: From Week 52 to End of the study (EOS) (December 2026)

  27. LTE Phase: Percentage of Participants Who Achieved IGA Score of (Cleared [0], Cleared [0] or Minimal [1], Mild or Better [<=2] Over Time

    Time frame: From Week 52 to EOS (December 2026)

  28. LTE Phase: Percent Improvement From Baseline in PASI Over Time

    Time frame: From Week 52 to EOS (December 2026)

  29. LTE Phase: Change From Baseline in BSA With Psoriasis Skin Involvement Over Time

    Time frame: From Week 52 to EOS (Dec 2026)

  30. LTE Phase: Percentage of Participants Who Achieved PASI Responses (PASI 50, 75, 90,and 100) at Weeks 60 and 84 After Retreatment Among Guselkumab Participants Who Were Withdrawn From Guselkumab at Week 16 and Retreated Upon Loss of Response or at Week 52

    Time frame: Week 60 and Week 84

  31. LTE Phase: Percentage of Participants Who Achieved IGA Score of (Cleared [0], Cleared [0] or Minimal [1], Mild or Better [<=2] at Weeks 60 and 84 After Retreatment

    Time frame: Week 60 and Week 84

  32. LTE Phase: Percent Improvement in PASI Responses (PASI 50, 75, 90, and 100) at Weeks 60 and 84 After Retreatment Among Guselkumab Subjects Who Were Withdrawn From Guselkumab at Week 16 and Subsequently Retreated Upon Loss of Response or at Week 52

    Time frame: Week 60 and Week 84

  33. LTE Phase: Change From Baseline in BSA at Weeks 60 and 84 After Retreatment Among Guselkumab Subjects Who Were Withdrawn From Guselkumab at Week 16 and Subsequently Retreated Upon Loss of Response or at Week 52

    Time frame: Week 60 and Week 84

07

Results

Posted Mar 28, 2025

Participant flow

PCP: Week 0 -16
Participant flow — PCP: Week 0 -16
MilestoneGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)Group 1 (Part 1): Placebo to Guselkumab (Week 16-52)Group 2 (Part 1): Guselkumab (Week 16-52)Group 3 (Part 1): Etanercept to Guselkumab (Week 16-52)Part 2: Guselkumab (Week 0-16)Part 2: Guselkumab (Week 16-52)
Started254126000280
Completed244123000270
Not completed10300010
Withdrew: Adverse event10000010
Withdrew: Withdrawal by subject00100000
Withdrew: Withdrawal by parent/guardian00200000
Withdrawal and Retreament: Week 16-52
Participant flow — Withdrawal and Retreament: Week 16-52
MilestoneGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)Group 1 (Part 1): Placebo to Guselkumab (Week 16-52)Group 2 (Part 1): Guselkumab (Week 16-52)Group 3 (Part 1): Etanercept to Guselkumab (Week 16-52)Part 2: Guselkumab (Week 0-16)Part 2: Guselkumab (Week 16-52)
Started000234122027
Completed000233521027
Not completed00006100
Withdrew: Other withdrawal by parent/guardian00003100
Withdrew: Other unspecified00001000
Withdrew: Other- completed safety follow up00002000

Outcome measures

PrimaryPart 1: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
At Week 16
Reported as:
Number · Percentages of participants
Part 1: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
Percentages of participantsGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 1616.065.969.2
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · Fisher Exact · p = <0.001 · Difference in percentage: 49.9 · 95% CI 25.9 to 69.4P-values represented the comparisons with placebo and were based on the Fisher's exact test stratified by age group and region (pooled).
PrimaryPart 1: Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16

The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 75 response represented participants who achieved at least a 75 % improvement from baseline in the PASI score.

Time frame:
At Week 16
Reported as:
Number · Percentage of Participants
Part 1: Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
Percentage of ParticipantsGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 1620.075.669.2
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · Fisher Exact · p = <0.001 · Difference in percentage: 55.6 · 95% CI 32.1 to 74.0P-values represented the comparisons with placebo and were based on the Fisher's exact test stratified by age group and region (pooled).
SecondaryPart 1: Percentage of Participants Who Achieve PASI 90 Response at Week 16

The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90 % improvement from baseline in the PASI score.

Time frame:
At Week 16
Reported as:
Number · Percentage of Participants
Part 1: Percentage of Participants Who Achieve PASI 90 Response at Week 16
Percentage of ParticipantsGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Percentage of Participants Who Achieve PASI 90 Response at Week 1616.056.153.8
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · Fisher Exact · p = =0.003 · Difference in percentage: 40.1 · 95% CI 15.6 to 61.3P-values represented the comparisons with placebo and were based on the Fisher's exact test stratified by age group and region (pooled).
SecondaryPart 1: Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
At Week 16
Reported as:
Number · Percentages of participants
Part 1: Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16
Percentages of participantsGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 164.039.026.9
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · Fisher Exact · p = =0.004 · Difference in percentage: 35 · 95% CI 10.5 to 56.8P-values represented the comparisons with placebo and were based on the Fisher's exact test stratified by age group and region (pooled).
SecondaryPart 1: Percentage of Participants Who Achieved PASI 100 Response at Week 16

The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 100 response represented participants who achieved a 100 % improvement from baseline in the PASI score.

Time frame:
At Week 16
Reported as:
Number · Percentages of participants
Part 1: Percentage of Participants Who Achieved PASI 100 Response at Week 16
Percentages of participantsGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Percentage of Participants Who Achieved PASI 100 Response at Week 16034.126.9
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · Fisher Exact · p = =0.002 · Difference in percentage: 34.1 · 25% CI 9.7 to 56.1P-values represented the comparisons with placebo and were based on the Fisher's exact test stratified by age group and region (pooled).
SecondaryPart 1: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Score at Week 16

CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. Change from baseline is defined as post baseline score minus baseline score.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a scale
Part 1: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Score at Week 16
Score on a scaleGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Score at Week 16-1.68 ± 6.323-7.12 ± 7.633-6.08 ± 5.692
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · Mixed model repeated measures (MMRM) · p = <0.001 · Ls mean difference: -5.4 · 95% CI -7.33 to -3.06
SecondaryPart 1: Percentage of Retreated Participants Who Achieved a PASI 90 Response Over Time After Retreatment

PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90 % improvement from baseline in PASI score.

Time frame:
At 4 and 8 weeks post retreatment (retreatment period ranged from Week 16 to Week 52)
Reported as:
Number · Percentages of participants
Part 1: Percentage of Retreated Participants Who Achieved a PASI 90 Response Over Time After Retreatment
Percentages of participantsGroup 2 (Part 1): Guselkumab (Week 16-52)
4 weeks after retreatment of guselkumab0
8 weeks after retreatment of guselkumab50.0
SecondaryPart 1: Percentage of Retreated Participants Who Achieved PASI Responses (PASI 50, 75, 90, and 100) Over Time After Retreatment

The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90 and 100 response represented at least 50, 75, 90 and 100% improvement from baseline respectively, in the PASI score.

Time frame:
At 4 and 8 weeks post retreatment (retreatment period ranged from Week 16 to Week 52)
Reported as:
Number · At 4 and 8 weeks post retreatment
Part 1: Percentage of Retreated Participants Who Achieved PASI Responses (PASI 50, 75, 90, and 100) Over Time After Retreatment
At 4 and 8 weeks post retreatmentGroup 2 (Part 1): Guselkumab (Week 16-52)
4 weeks after retreatment: >=50% improvement50.0
4 weeks after retreatment: >=75% improvement0
4 weeks after retreatment:>= 90% improvement0
4 weeks after retreatment: 100% improvement0
8 weeks after retreatment: >=50% improvement50.0
8 weeks after retreatment: >=75% improvement50.0
8 weeks after retreatment:>= 90% improvement50.0
8 weeks after retreatment: 100% improvement50.0
SecondaryPart 1: Percentage of Retreated Participants Who Achieved IGA Responses (IGA of Cleared [0], Minimal [1], or Mild [2], IGA of Cleared [0] or Minimal [1], and IGA of Cleared [0]) Over Time After Retreatment

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
At 4 and 8 weeks post retreatment (retreatment period ranged from Week 16 to Week 52)
Reported as:
Number · Percentages of participants
Part 1: Percentage of Retreated Participants Who Achieved IGA Responses (IGA of Cleared [0], Minimal [1], or Mild [2], IGA of Cleared [0] or Minimal [1], and IGA of Cleared [0]) Over Time After Retreatment
Percentages of participantsGroup 2 (Part 1): Guselkumab (Week 16-52)
4 Weeks after retreatment: IGA-00
4 Weeks after retreatment: IGA-0 or 125.0
4 Weeks after retreatment: IGA-275.0
8 Weeks after retreatment: IGA-050.0
8 Weeks after retreatment: IGA-0 or 150.0
8 Weeks after retreatment: IGA- 2100.0
SecondaryPart 1: Cumulative Rate of Loss of at Least 50% of Week 16 PASI Improvement Through Week 52 Among Guselkumab PASI 90 Responders at Week 16

Cumulative rate of loss of at least 50% of PASI improvement was defined as percentage of participants with a loss of \>=50% of Week 16 PASI improvement after treatment is withdrawn. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease.

Time frame:
Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of Participants
Part 1: Cumulative Rate of Loss of at Least 50% of Week 16 PASI Improvement Through Week 52 Among Guselkumab PASI 90 Responders at Week 16
Percentage of ParticipantsGroup 2 (Part 1): Guselkumab (Week 16-52)
Week 200
Week 240
Week 280
Week 320
Week 360
Week 400
Week 449.3
Week 4819.1
Week 5219.1
SecondaryPart 1: Cumulative Maintenance Rate of PASI 90 Response Through Week 52 Among Guselkumab PASI 90 Responders at Week 16

Cumulative maintenance rate was defined as percentage of participants who maintained their PASI 90 response through Week 52 among guselkumab PASI 90 responders at Week 16. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90% improvement from baseline in PASI score.

Time frame:
Week 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of participants
Part 1: Cumulative Maintenance Rate of PASI 90 Response Through Week 52 Among Guselkumab PASI 90 Responders at Week 16
Percentage of participantsGroup 2 (Part 1): Guselkumab (Week 16-52)
Week 20100
Week 24100
Week 2886.7
Week 3277.5
Week 3663.9
Week 4050.2
Week 4435.8
Week 4830.7
Week 5225.6
SecondaryPart 1: Percentage of Participants Who Achieved a PASI 50 Response at Week 16

The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 50 response represented at least a 50% improvement from baseline in the PASI score.

Time frame:
At Week 16
Reported as:
Number · Percentages of participants
Part 1: Percentage of Participants Who Achieved a PASI 50 Response at Week 16
Percentages of participantsGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Percentage of Participants Who Achieved a PASI 50 Response at Week 1628.087.876.9
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · Fisher Exact · p = <0.001 (p-value is nominal) · Difference in percentage: 59.8 · 95% CI 36.9 to 77.6P-values represented the comparisons with placebo and were based on the Fisher's exact test stratified by age group and region (pooled).
SecondaryPart 1: Percent Improvement From Baseline in PASI Through Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease.

Time frame:
Weeks 4, 8, 12, and 16
Reported as:
Mean · Percent improvement
Part 1: Percent Improvement From Baseline in PASI Through Week 16
Percent improvementGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Week 413.37 ± 30.07439.12 ± 27.90742.53 ± 26.013
Week 813.61 ± 40.73471.25 ± 28.01864.27 ± 29.314
Week 1213.67 ± 52.39179.79 ± 28.57077.30 ± 24.735
Week 1616.02 ± 55.53879.83 ± 30.46882.05 ± 23.225
SecondaryPart 2: Percent Improvement From Baseline in PASI Through Week 52

The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease.

Time frame:
Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52
Reported as:
Mean · Percent improvement
Part 2: Percent Improvement From Baseline in PASI Through Week 52
Percent improvementPart 2: Guselkumab (Week 0-52)
Week 448.33 ± 26.781
Week 879.05 ± 21.177
Week 1286.40 ± 15.541
Week 1691.96 ± 11.177
Week 2091.10 ± 14.851
Week 2893.44 ± 12.948
Week 3695.77 ± 7.848
Week 4495.95 ± 7.430
Week 5296.32 ± 7.478
SecondaryPart 1: Percentage of Participants With PASI Responses (PASI 50, 75, 90, and 100) Through Week 16

The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90, and 100 responses represented at least 50%, 75%, 90%, and 100% improvement from baseline respectively, in the PASI score.

Time frame:
Weeks 4, 8, 12, and 16
Reported as:
Number · Percentages of participants
Part 1: Percentage of Participants With PASI Responses (PASI 50, 75, 90, and 100) Through Week 16
Percentages of participantsGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Week 4: >= 50% improvement8.034.138.5
Week 4: >= 75% improvement8.012.215.4
Week 4: >= 90% improvement4.02.43.8
Week 4: 100% improvement000
Week 8: >= 50% improvement20.078.073.1
Week 8: >= 75% improvement8.051.246.2
Week 8: >= 90% improvement4.034.119.2
Week 8: 100% improvement4.012.211.5
Week 12: >= 50% improvement24.085.476.9
Week 12: >= 75% improvement12.073.261.5
Week 12: >= 90% improvement8.056.138.5
Week 12: 100% improvement034.126.9
Week 16: >= 50% improvement28.087.876.9
Week 16: >= 75% improvement20.075.669.2
Week 16: >= 90% improvement16.056.153.8
Week 16: 100% improvement034.126.9
SecondaryPart 2: Percentage of Participants With PASI Responses (PASI 50, 75, 90, and 100) Through Week 52

The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90, and 100 responses represented at least 50%, 75%, 90%, and 100% improvement from baseline respectively, in the PASI score.

Time frame:
Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52
Reported as:
Number · Percentages of participants
Part 2: Percentage of Participants With PASI Responses (PASI 50, 75, 90, and 100) Through Week 52
Percentages of participantsPart 2: Guselkumab (Week 0-52)
Week 4: >= 50% improvement42.9
Week 4: >= 75% improvement14.3
Week 4: >= 90% improvement14.3
Week 4: 100% improvement3.6
Week 8: >= 50% improvement89.3
Week 8: >= 75% improvement67.9
Week 8: >= 90% improvement39.3
Week 8: 100% improvement17.9
Week 12: >= 50% improvement96.4
Week 12: >= 75% improvement75.0
Week 12: >= 90% improvement42.9
Week 12: 100% improvement25.0
Week 16: >= 50% improvement92.9
Week 16: >= 75% improvement82.1
Week 16: >= 90% improvement64.3
Week 16: 100% improvement35.7
Week 20: >= 50% improvement92.9
Week 20: >= 75% improvement82.1
Week 20: >= 90% improvement75.0
Week 20: 100% improvement39.3
Week 28: >= 50% improvement92.9
Week 28: >= 75% improvement89.3
Week 28: >= 90% improvement75.0
Week 28: 100% improvement46.4
Week 36: >= 50% improvement96.4
Week 36: >= 75% improvement89.3
Week 36: >= 90% improvement82.1
Week 36: 100% improvement53.6
Week 44: >= 50% improvement96.4
Week 44: >= 75% improvement89.3
Week 44: >= 90% improvement82.1
Week 44: 100% improvement53.6
Week 52: >= 50% improvement96.4
Week 52: >= 75% improvement92.9
Week 52: >= 90% improvement82.1
Week 52: 100% improvement53.6
SecondaryPart 1: Percentage of Participants With IGA of Cleared (0), Cleared (0) or Minimal (1), Mild or Better (<=2) Through Week 16

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
Weeks 4, 8, 12, and 16
Reported as:
Number · Percentages of participants
Part 1: Percentage of Participants With IGA of Cleared (0), Cleared (0) or Minimal (1), Mild or Better (<=2) Through Week 16
Percentages of participantsGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Week 4 : IGA of cleared (0)000
Week 4 : IGA of cleared (0) or minimal (1)8.019.523.1
Week 4 :IGA of mild or better (<=2)20.063.473.1
Week 8: IGA of cleared (0)4.022.011.5
Week 8 : IGA of cleared (0) or minimal (1)8.058.550.0
Week 8 :IGA of mild or better (<=2)24.078.088.5
Week 12: IGA of cleared (0)4.043.926.9
Week 12 : IGA of cleared (0) or minimal (1)8.070.765.4
Week 12 :IGA of mild or better (<=2)40.087.884.6
Week 16: IGA of cleared (0)4.039.026.9
Week 16 : IGA of cleared (0) or minimal (1)16.065.969.2
Week 16 :IGA of mild or better (<=2)48.092.784.6
SecondaryPart 2: Percentage of Participants With IGA of Cleared (0), Cleared (0) or Minimal (1), Mild or Better (<=2) Through Week 52

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52
Reported as:
Number · Percentages of participants
Part 2: Percentage of Participants With IGA of Cleared (0), Cleared (0) or Minimal (1), Mild or Better (<=2) Through Week 52
Percentages of participantsPart 2: Guselkumab (Week 0-52)
Week 4: IGA of cleared (0)3.6
Week 4: IGA of cleared (0) or minimal (1)25.0
Week 4:IGA of mild or better (<=2)57.1
Week 8: IGA of cleared (0)25.0
Week 8: IGA of cleared (0) or minimal (1)64.3
Week 8:IGA of mild or better (<=2)92.9
Week 12: IGA of cleared (0)35.7
Week 12: IGA of cleared (0) or minimal (1)75.0
Week 12:IGA of mild or better (<=2)96.4
Week 16: IGA of cleared (0)46.4
Week 16: IGA of cleared (0) or minimal (1)89.3
Week 16:IGA of mild or better (<=2)92.9
Week 20: IGA of cleared (0)50.0
Week 20: IGA of cleared (0) or minimal (1)82.1
Week 20:IGA of mild or better (<=2)96.4
Week 28: IGA of cleared (0)57.1
Week 28: IGA of cleared (0) or minimal (1)78.6
Week 28:IGA of mild or better (<=2)96.4
Week 36: IGA of cleared (0)64.3
Week 36: IGA of cleared (0) or minimal (1)89.3
Week 36:IGA of mild or better (<=2)89.3
Week 44: IGA of cleared (0)64.3
Week 44: IGA of cleared (0) or minimal (1)85.7
Week 44: IGA of mild or better (<=2)89.3
Week 52: IGA of cleared (0)75.0
Week 52: IGA of cleared (0) or minimal (1)85.7
Week 52: IGA of mild or better (<=2)92.9
SecondaryPart 2: Change From Baseline in CDLQI Score Through Week 52

Change from baseline in CDLQI score through Week 52 were reported. CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.

Time frame:
Baseline, Weeks 8, 16, 28, 36, and 52
Reported as:
Mean · Score on a scale
Part 2: Change From Baseline in CDLQI Score Through Week 52
Score on a scalePart 2: Guselkumab (Week 0-52)
Week 8-5.6 ± 6.40
Week 16-6.8 ± 6.32
Week 28-6.7 ± 6.54
Week 36-7.0 ± 6.88
Week 52-7.3 ± 6.83
SecondaryPart 1: Percentage of Participants With CDLQI Score Equal to 0 or 1 at Week 16 Among Participants With a Baseline CDLQI Score Greater Than (>) 1

CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.

Time frame:
At Week 16
Reported as:
Number · Percentages of participants
Part 1: Percentage of Participants With CDLQI Score Equal to 0 or 1 at Week 16 Among Participants With a Baseline CDLQI Score Greater Than (>) 1
Percentages of participantsGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Percentage of Participants With CDLQI Score Equal to 0 or 1 at Week 16 Among Participants With a Baseline CDLQI Score Greater Than (>) 117.464.138.5
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · Fisher Exact · p = =0.002 (p-value is nominal) · Difference in percentage: 46.7 · 95% CI 21.9 to 67.3P-values represented the comparisons with placebo and were based on the Fisher's exact test stratified by age group and region (pooled).
SecondaryPart 2: Percentage of Participants With CDLQI Score Equal to of 0 or 1 Through Week 52 Among Participants With a Baseline CDLQI Score > 1

CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.

Time frame:
Weeks 8, 16, 28, 36, and 52
Reported as:
Number · Percentages of participants
Part 2: Percentage of Participants With CDLQI Score Equal to of 0 or 1 Through Week 52 Among Participants With a Baseline CDLQI Score > 1
Percentages of participantsPart 2: Guselkumab (Week 0-52)
Week 850.0
Week 1658.3
Week 2866.7
Week 3662.5
Week 5266.7
SecondaryPart 1: Percentage of Participants With Family Dermatology Life Quality Index (FDLQI) of 0 or 1 at Week 16 Among Participants With a Baseline FDLQI >1

The FDLQI was a 10-item questionnaire that examined the impact of participant's skin disease on different aspects of their QoL (example: emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) were added to give a total scale score that ranged from 0 to 30; a higher score indicated greater impairment of QoL.

Time frame:
At Week 16
Reported as:
Number · Percentages of participants
Part 1: Percentage of Participants With Family Dermatology Life Quality Index (FDLQI) of 0 or 1 at Week 16 Among Participants With a Baseline FDLQI >1
Percentages of participantsGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Percentage of Participants With Family Dermatology Life Quality Index (FDLQI) of 0 or 1 at Week 16 Among Participants With a Baseline FDLQI >113.036.124.0
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · Fisher Exact · p = =0.139 (p-value is nominal) · Difference in percentage: 23.1 · 95% CI -3.4 to 47.0P-values represented the comparisons with placebo and were based on the Fisher's exact test stratified by age group and region (pooled).
SecondaryPart 2: Percentage of Participants With Family Dermatology Life Quality Index (FDLQI) of 0 or 1 Through Week 52 Among Participants With a Baseline FDLQI >1

The FDLQI was a 10-item questionnaire that examine the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) were added to give a total scale score that ranged from 0 to 30; a higher score indicates greater impairment of QoL.

Time frame:
Weeks 8, 16, 28, 36, and 52
Reported as:
Number · Percentages of participants
Part 2: Percentage of Participants With Family Dermatology Life Quality Index (FDLQI) of 0 or 1 Through Week 52 Among Participants With a Baseline FDLQI >1
Percentages of participantsPart 2: Guselkumab (Week 0-52)
Week 827.3
Week 1631.8
Week 2859.1
Week 3636.4
Week 5250.0
SecondaryPart 1: Change From Baseline in FDLQI Score at Week 16

The FDLQI was a 10-item questionnaire that examined the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) are added to give a total scale score that ranged from 0 to 30; a higher score indicates greater impairment of QoL.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a scale
Part 1: Change From Baseline in FDLQI Score at Week 16
Score on a scaleGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Change From Baseline in FDLQI Score at Week 16-0.50 ± 6.984-6.22 ± 6.299-6.22 ± 4.814
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · MMRM model · p = <0.001 (p-value is nominal) · Difference in ls mean: -5.44 · 95% CI -8.00 to -2.87
SecondaryPart 2: Change From Baseline in FDLQI Score Through Week 52

The FDLQI was a 10-item questionnaire that examine the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) are added to give a total scale score that ranged from 0 to 30; a higher score indicated greater impairment of QoL.

Time frame:
Baseline, Weeks 8, 16, 28, 36, and 52
Reported as:
Mean · Score on scale
Part 2: Change From Baseline in FDLQI Score Through Week 52
Score on scalePart 2: Guselkumab (Week 0-52)
Week 8-5.4 ± 5.58
Week 16-5.5 ± 5.90
Week 28-7.5 ± 6.15
Week 36-6.7 ± 5.00
Week 52-7.8 ± 5.68
SecondaryPart 1: Change From Baseline in Body Surface Area (BSA) With Psoriasis Skin Involvement at Week 16

Change from baseline in percent body surface area with psoriasis skin involvement was reported. BSA as physical measure to define disease severity is to determine how much of the BSA is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.

Time frame:
Baseline and Week 16
Reported as:
Mean · Units on a scale
Part 1: Change From Baseline in Body Surface Area (BSA) With Psoriasis Skin Involvement at Week 16
Units on a scaleGroup 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)
Part 1: Change From Baseline in Body Surface Area (BSA) With Psoriasis Skin Involvement at Week 16-2.84 ± 13.861-19.59 ± 17.645-17.50 ± 10.628
Statistical analysis
  • Group 1 (Part 1): Placebo (Week 0-16) vs Group 2 (Part 1): Guselkumab (Week 0-16) · MMRM model · p = <0.001 (p-value is nominal) · Ls mean difference: -14.78 · 95% CI -20.28 to -9.28
SecondaryParts 2: Change From Baseline in BSA With Psoriasis Skin Involvement Over Time Through Week 52

Change from baseline in percent body surface area with psoriasis skin involvement was reported. BSA as physical measure to define disease severity is to determine how much of the BSA is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52
Reported as:
Mean · Units on a scale
Parts 2: Change From Baseline in BSA With Psoriasis Skin Involvement Over Time Through Week 52
Units on a scalePart 2: Guselkumab (Week 0-52)
Week 4-6.9 ± 7.94
Week 8-16.8 ± 12.00
Week 12-19.6 ± 12.58
Week 16-22.7 ± 13.57
Week 20-24.0 ± 13.46
Week 28-26.0 ± 14.61
Week 36-26.3 ± 14.42
Week 44-26.5 ± 14.05
Week 52-26.4 ± 14.52
SecondaryLTE Phase: Percentage of Participants Who Achieved PASI Responses (PASI 50, 75, 90, and 100) Over Time
Time frame:
From Week 52 to End of the study (EOS) (December 2026)

Results for this outcome have not been posted.

SecondaryLTE Phase: Percentage of Participants Who Achieved IGA Score of (Cleared [0], Cleared [0] or Minimal [1], Mild or Better [<=2] Over Time
Time frame:
From Week 52 to EOS (December 2026)

Results for this outcome have not been posted.

SecondaryLTE Phase: Percent Improvement From Baseline in PASI Over Time
Time frame:
From Week 52 to EOS (December 2026)

Results for this outcome have not been posted.

SecondaryLTE Phase: Change From Baseline in BSA With Psoriasis Skin Involvement Over Time
Time frame:
From Week 52 to EOS (Dec 2026)

Results for this outcome have not been posted.

SecondaryLTE Phase: Percentage of Participants Who Achieved PASI Responses (PASI 50, 75, 90,and 100) at Weeks 60 and 84 After Retreatment Among Guselkumab Participants Who Were Withdrawn From Guselkumab at Week 16 and Retreated Upon Loss of Response or at Week 52
Time frame:
Week 60 and Week 84

Results for this outcome have not been posted.

SecondaryLTE Phase: Percentage of Participants Who Achieved IGA Score of (Cleared [0], Cleared [0] or Minimal [1], Mild or Better [<=2] at Weeks 60 and 84 After Retreatment
Time frame:
Week 60 and Week 84

Results for this outcome have not been posted.

SecondaryLTE Phase: Percent Improvement in PASI Responses (PASI 50, 75, 90, and 100) at Weeks 60 and 84 After Retreatment Among Guselkumab Subjects Who Were Withdrawn From Guselkumab at Week 16 and Subsequently Retreated Upon Loss of Response or at Week 52
Time frame:
Week 60 and Week 84

Results for this outcome have not been posted.

SecondaryLTE Phase: Change From Baseline in BSA at Weeks 60 and 84 After Retreatment Among Guselkumab Subjects Who Were Withdrawn From Guselkumab at Week 16 and Subsequently Retreated Upon Loss of Response or at Week 52
Time frame:
Week 60 and Week 84

Results for this outcome have not been posted.

Adverse events

Collected over PCP (Part 1): Week 0 to 16; Withdrawal and re-treatment period (Part 1): Week 16 to 52; Part 2: Week 0 to 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PCP-Group 1 (Part 1): Placebo (Week 0-16)0/25 (0%)0/25 (0%)17/25 (68%)
PCP-Group 2 (Part 1): Guselkumab (Week 0-16)0/41 (0%)1/41 (2.4%)17/41 (41.5%)
PCP-Group 3 (Part 1): Etanercept (Week 0-16)0/26 (0%)0/26 (0%)15/26 (57.7%)
Withdrawal and Re-treatment Period-Group 1 (Part 1): Placebo to Guselkumab (Week 16-52)0/23 (0%)1/23 (4.3%)16/23 (69.6%)
Withdrawal and Re-treatment Period-Group 2 (Part 1): Guselkumab (Week 16-52)0/41 (0%)0/41 (0%)29/41 (70.7%)
Withdrawal and Re-treatment Period- Group 3 (Part 1): Etanercept to Guselkumab (Week 16-52)0/22 (0%)0/22 (0%)13/22 (59.1%)
Part 2: Guselkumab (Week 0-52)0/28 (0%)1/28 (3.6%)23/28 (82.1%)
Most frequent serious events
Most frequent serious events
EventPCP-Group 1 (Part 1): Placebo (Week 0-16)PCP-Group 2 (Part 1): Guselkumab (Week 0-16)PCP-Group 3 (Part 1): Etanercept (Week 0-16)Withdrawal and Re-treatment Period-Group 1 (Part 1): Placebo to Guselkumab (Week 16-52)Withdrawal and Re-treatment Period-Group 2 (Part 1): Guselkumab (Week 16-52)Withdrawal and Re-treatment Period- Group 3 (Part 1): Etanercept to Guselkumab (Week 16-52)Part 2: Guselkumab (Week 0-52)
Chronic TonsillitisInfections and infestations0/250/410/261/230/410/220/28
Multiple InjuriesInjury, poisoning and procedural complications0/250/410/260/230/410/221/28
Radius FractureInjury, poisoning and procedural complications0/251/410/260/230/410/220/28
Most frequent other events
Showing 10 of 116
Most frequent other events
EventPCP-Group 1 (Part 1): Placebo (Week 0-16)PCP-Group 2 (Part 1): Guselkumab (Week 0-16)PCP-Group 3 (Part 1): Etanercept (Week 0-16)Withdrawal and Re-treatment Period-Group 1 (Part 1): Placebo to Guselkumab (Week 16-52)Withdrawal and Re-treatment Period-Group 2 (Part 1): Guselkumab (Week 16-52)Withdrawal and Re-treatment Period- Group 3 (Part 1): Etanercept to Guselkumab (Week 16-52)Part 2: Guselkumab (Week 0-52)
NasopharyngitisInfections and infestations7/255/413/268/239/414/227/28
Covid-19Infections and infestations0/251/410/260/231/411/226/28
Upper Respiratory Tract InfectionInfections and infestations2/254/412/260/236/413/222/28
AcneSkin and subcutaneous tissue disorders0/251/410/260/232/410/223/28
GastroenteritisInfections and infestations0/250/410/260/231/412/220/28
HeadacheNervous system disorders0/253/411/262/233/412/222/28
FatigueGeneral disorders0/250/412/260/231/410/221/28
BronchitisInfections and infestations0/250/412/261/231/411/220/28
ArthralgiaMusculoskeletal and connective tissue disorders0/250/412/260/232/410/221/28
Respiratory Tract InfectionInfections and infestations0/250/410/260/230/410/222/28

Baseline characteristics

Age, Customized
Age, Customized(Participants)Group 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)Part 2: Guselkumab (Week 0-16)Total
>=6 to <12 years101010030
>=12 to <18 years1531162890
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)Part 2: Guselkumab (Week 0-16)Total
Female1317111152
Male1224151768
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)Part 2: Guselkumab (Week 0-16)Total
American Indian or Alaska Native00000
Asian11204
Black or African American21104
Native Hawaiian or Other Pacific Islander00000
White20362228106
More than one race01102
Unknown or Not Reported10001
Other12003
Region of Enrollment
Region of Enrollment(participants)Group 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)Part 2: Guselkumab (Week 0-16)Total
AUSTRALIA01001
BELGIUM045211
CANADA15118
GERMANY445922
HUNGARY6114930
ITALY441110
NETHERLANDS12003
POLAND576624
UNITED STATES434011
AgeContinuous
AgeContinuous(years)Group 1 (Part 1): Placebo (Week 0-16)Group 2 (Part 1): Guselkumab (Week 0-16)Group 3 (Part 1): Etanercept (Week 0-16)Part 2: Guselkumab (Week 0-16)Total
Mean12.4 ± 3.6313.4 ± 2.8612.5 ± 3.2915.1 ± 1.5913.4 ± 3.05
08

Study locations

39 sites
09

References and documents

Publications

  • Crauwels H, Ringold S, Howard S, Van Hartingsveldt B, Smith V, Jett M, Baguet T, Adamson E, Chakravarty SD, Leu JH. Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data. Paediatr Drugs. 2026 Jan;28(1):69-81. doi: 10.1007/s40272-025-00725-2. Epub 2025 Oct 28. PubMed 41152645 ↗
  • Prajapati VH, Seyger MMB, Wilsmann-Theis D, Szakos E, Kaszuba A, van Hartingsveldt B, Jett M, Jiang G, Li S, Sinha V, Crauwels H, DeKlotz CMC, Paller AS. Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study. Br J Dermatol. 2025 Mar 18;192(4):618-628. doi: 10.1093/bjd/ljae502. PubMed 39708367 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jul 2023, 60 months.

Results were first posted in Mar 2025, 1 year 8 months after primary completion. A results delay was requested in Jul 2024.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 60 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2018
First posted
Mar 2, 2018
StartActual
Jul 11, 2018
Primary completionActual
Jul 19, 2023
CompletionEst.
Dec 18, 2026
Results delay requested
Jul 16, 2024
Results first posted
Mar 28, 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03451851
Responsible party
Sponsor
First posted
Mar 2, 2018
Start date
Jul 11, 2018
Primary completion
Jul 19, 2023
Completion
Dec 18, 2026 (estimated)
Results posted
Mar 28, 2025
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion